Nidorf M - Search Results

1

Colchicine for prevention of cardiovascular events.

Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M. Hemkens LG, et al. Among authors: nidorf m. Cochrane Database Syst Rev. 2016 Jan 27;2016(1):CD011047. doi: 10.1002/14651858.CD011047.pub2. Cochrane Database Syst Rev. 2016. PMID: 26816301 Free PMC article. Review.

2

Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.

Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M. Hemkens LG, et al. Among authors: nidorf m. Heart. 2016 Apr;102(8):590-6. doi: 10.1136/heartjnl-2015-308542. Epub 2016 Feb 1. Heart. 2016. PMID: 26830663 Review.

3

Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease.

Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, Liew D, Imazio M, Cornel JH, Thompson PL, Nidorf M. Robinson PC, et al. Among authors: nidorf m. Am J Med. 2022 Jan;135(1):32-38. doi: 10.1016/j.amjmed.2021.07.025. Epub 2021 Aug 18. Am J Med. 2022. PMID: 34416165 Free PMC article. Review.

4

Colchicine and the heart.

Imazio M, Nidorf M. Imazio M, et al. Among authors: nidorf m. Eur Heart J. 2021 Jul 21;42(28):2745-2760. doi: 10.1093/eurheartj/ehab221. Eur Heart J. 2021. PMID: 33961006 Free PMC article. Review.

5

Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.

Nidorf M, Thompson PL. Nidorf M, et al. Am J Cardiol. 2007 Mar 15;99(6):805-7. doi: 10.1016/j.amjcard.2006.10.039. Epub 2007 Jan 16. Am J Cardiol. 2007. PMID: 17350370 Clinical Trial.

6

Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS).

McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL. McQuillan BM, et al. Among authors: nidorf m. J Am Coll Cardiol. 2001 Dec;38(7):1788-94. doi: 10.1016/s0735-1097(01)01676-x. J Am Coll Cardiol. 2001. PMID: 11738275 Free article.

7

Coronary thrombolysis: an important therapy for myocardial infarction.

Nidorf M, Thompson PL. Nidorf M, et al. Med J Aust. 1988 Oct 3;149(7):376-80. doi: 10.5694/j.1326-5377.1988.tb120674.x. Med J Aust. 1988. PMID: 3050397 Review. No abstract available.

8

Refining the risk-benefit equation for thrombolysis: how to identify the low risk patient before administering thrombolytic therapy.

Nidorf M, Parsons R, Thompson P, Jamrozik K, Hobbs M. Nidorf M, et al. Aust N Z J Med. 1998 Aug;28(4):525-8. doi: 10.1111/j.1445-5994.1998.tb02104.x. Aust N Z J Med. 1998. PMID: 9777133

9

Coronary thrombolysis.

Thompson PL, Nidorf M. Thompson PL, et al. Among authors: nidorf m. Med J Aust. 1989 Apr 17;150(8):466-7. Med J Aust. 1989. PMID: 2497312 No abstract available.

10

Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS).

McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. McQuillan BM, et al. Among authors: nidorf m. Circulation. 1999 May 11;99(18):2383-8. doi: 10.1161/01.cir.99.18.2383. Circulation. 1999. PMID: 10318658

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page